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INTRODUCTION
Lipid mediators participate in intercellular interactions as a 
paracrine signaling system which has evolved over a period of 
600 million years in primitive metazoans: sponges and corals. 
In humans, these mediators contribute to any inflammation, 
and there is a pertinent question of how is this specific for asth-
matic inflammation. Since the first description of the slow reac-
tion smooth muscle-stimulating substance (SRS-A) by Feldberg 
and Kelloway 75 years ago, lipid mediators have been investi-
gated in allergic reactions and bronchospasm. Advancements 
in clinical biochemistry made it possible to identify chemical 
structure, biosynthetic pathways, and cellular receptors of lipid 
mediators, and there were some novel ones identified during 
the last decade. These biological compounds became not only 
recognizable but also measurable in clinical samples due to de-
velopment of affordable chromatography-mass spectrometry 
equipment or sensitive immunoassays. Some recent advances 
in understanding of the signaling by eicosanoid mediators dur-
ing asthmatic inflammation are presented. Special attention is 
paid to aspirin-exacerbated respiratory disease (AERD), a phe-
notype of asthma manifested by the most profound changes in 
eicosanoids. Novel drugs inhibiting signaling or metabolism of 
eicosanoids are currently under development. It will require 
population studies to prove their efficacy in inflammation of 
the airways because contribution of eicosanoids to asthma is 
highly variable among asthmatics.
BIOSYNTHETIC PATHWAYS OF LIPID MEDIATORS
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eicosanoids. This name describes 20 carbon backbones of 
abundant polyunsaturated fatty acids in the organism (Fig. 1). 
Among them, arachidonic acid, an omega-6 fatty acid with 4 
polyunsaturated bonds, is a precursor of the most biologically 
potent lipid mediators. Biosynthetic pathway of eicosanoids in-
volves either non-enzymatic or stereospecific enzyme-cata-
lyzed oxidative reactions. Non-enzymatic oxidation affects 
polyunsaturated fatty acids at their storage site, which are ester-
ified to phospholipids constituting the cell membrane. This ox-
idation may happen during any biochemical reaction produc-
ing free oxygen radicals in the organism. Particularly, it follows 
the oxidative burst of activated granulocytes. Produced oxy-
lipins are named isoprostanes because their common signa-
ture is a stereochemical conformation different from mediators 
produced in enzymatic reactions. Isoprostanes are released 
from the cell membranes by the activity of phospholipases be-
fore they can exert any biological function. It is now widely ac-
cepted that isoprostanes activate the thromoboxane receptor 
and that their biological activity is similar to that of thrombox-
ane A2.1 Specific enzymes, which oxidize free polyunsaturated 
fatty acids released by phospholipases, regulate rate-limiting 
production of eicosanoids (Fig. 1). These enzymes are known 
as lipoxygenases or cyclooxygenases. Different lipoxygenases 
preferentially oxidize polyunsaturated fatty acids at their cer-
tain carbons, as counted from the carboxyl group carbon, and 
some products named R or S may differ by stereochemistry. 
There are several human enzymes capable of oxidizing polyun-
saturated fatty acids (Fig. 2). During inflammation, cellular 5-, 
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Fig. 1. Chemical structure and numbering of carbon atoms in polyusnaturatedfaty acid precursor of oxylipins. Gamma-linolenic acid (GLA), precursor of prostaglan-
din-1 series. This is not metabolized to leukotrienes but prostanoids: prostaglandin E1 or thromboxane A1 has an anti-inflammatory activity. Arachidonic acid (ARA): 
common precursor of the most active biologically prostanoids and leukotrienes. Eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids are ω-3 polyunsaturated 
fatty acids. EPA is a precursor of prostanoid-3 series, leukotrienes-5 series, or resolvin E1. DHA is a precursor of resolvins, protectins D, and maresins with proresolv-
ing activity.
5-HETE
12-HETE
15-HETE
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Fig. 2. Arachidonic acid is a substrate for lipoxygenase and cyclooxygenases. While 5-lipooxygenase (5-LO) is expressed in myeloid cells (neutrophils, basophils, eo-
sinophils, platelets, and mast cells), 12-LO and 15-LO are expressed in epithelia, keratinocytes,eosinophils, and monocytes/macrophages. Both cyclooxygenase-1 
(COX-1) and cyclooxygenase-2 (COX-2) produce the common precursors (PGH2) of prostaglandins thromboxane and prostacyclin.
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15, or 12-lipoxygenases are activated, and some studies have 
associated their genetic variants with particular phenotypes of 
inflammation.2 Another site-specific oxidation, at terminal 
ω-carbon number 20 is catalyzed by monooxygenases belong-
ing to the cytochrome P450 family (CYP4A11, CYP4A22, CY-
P4F2, and CYP4F3) and contributes to the metabolic degrada-
tion pathway of eicosanoids.3 This takes place in the microsom-
al fraction of the liver or in the kidney and is accompanied by 
β-oxidation, shortening the carbon backbone of oxylipins. A di-
rect product of lipoxygenation of arachidonic acid is a hydro-
peroxide of eicosatetraenoic acid (HpETE), but this intermedi-
ate is quickly reduced to an ordinary hydroxyl group of hy-
droxy-eicosatetraenoic acid (HETE). A more complex metabo-
lism can occur downstream lipoxygenation pathways, involv-
ing production of glutathione conjugates (Fig. 3). Activity of 
5-lipoxygenase (5-LO) results in production of 5-HPETE. This 
intermediate is oxidized again by the same enzyme to form leu-
kotriene A4 (LTA4), a parent compound of the leukotriene fami-
ly. Depending on the cell type and specific expression of en-
zymes, LTA4 is either hydrolyzed to a potent neutrophil che-
moattractant leukotriene B4 (LTB4) or conjugated with glutathi-
one to form leukotriene C4 (LTC4). LTC4 is equipotent with leu-
kotriene D4 (LTD4) produced by γ-glutamyl transpeptidase. 
However, the most stable and the least potent is leukotriene E4 
(LTE4) produced by dipeptidase cleavage of LTC4. Altogether 
these lipid mediators are named cysteinyl leukotrienes (CysLTs) 
and correspond to SRS-A formed in the allergic lung. Since LTA4 
is easily diffusible across biological membranes, leukotrienes 
can be produced as transcellular mediators of inflammation. In 
the bloodstream, the most common transcellular metabolism 
occurs between activated granulocytes producing LTA4 and 
granulocyte adherent platelets expressing LTC4 synthase. Plate-
lets do not have 5-LO activity, whereas neutrophils do not have 
LTC4 synthase; thus, biosynthesis of LTC4 is complemented only 
in neutrophil-platelet aggregates. An analogous family of vaso-
active mediators produced by 15-LO and conjugated to gluta-
thione is named eoxins,4 whereas cysteinyl-hepoxilins are pro-
duced from the 12-LO pathway.5
Prostanoids represent a subset of eicosanoid mediators pro-
duced by oxidation of polyunsaturated fatty acids in a cyclooxy-
genase pathway. Their chemical structure is distinguished by a 
common a 5 carbon cyclopentane ring, which is formed during 
the 2-step enzymatic activity of cyclooxygenases. There are 2 
genes encoding cyclooxygenases (prostaglandin G synthases) 
in humans: PTGS1 and PTGS2. These enzymes are named cy-
clooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). An-
other protein encoded by the same PTGS1 gene was named 
PTGS-1b or COX-3. It has initially been described as translated 
from the splicing variant of PTGS1 transcript and particularly 
sensitive to acetaminophen inhibition with a limited tissue dis-
tribution. However, the latest report questioned the presence of 
enzymatically active COX-3 in humans and showed maturation 
of the PTGS-1b transcript to a normal COX-1.6 For simplicity, it 
is assumed that COX-1 expression is mostly constitutive, where-
as COX-2 is an inducible enzyme. Both enzymes produce the 
same unstable intermediates: PGG2/H2, which are metabolized 
to the prostaglandins PGE2, and PGD2, and PGF2 by specific 
synthases. In the vascular system, PGH2 is also metabolized to 
thromboxane A2(TXA2) by platelets and to prostacyclin (PGI2) 
by endothelial cells.
Another group of eicosanoid mediators can be produced in 
the inflammatory milieu by metabolic steps dependent on in-
tercellular cooperation. These are named pro-resolving eico-
sanoids because they terminate inflammatory reactions by ac-
tivation of macrophage phagocytosis, without usual release of 
pro-inflammatory cytokines.7 It was recently discovered, that 
pro-resolving eicosanoids can also be conjugated to glutathi-
one at the site of inflammation and retain a potent biological 
activity.8,9 Lipoxin (LXA4) was described as the first pro-resolv-
ing eicosanoid. Arachidonic acid is metabolized to lipoxins by a 
concerted action of lipoxygenases (5-LO + 12-LO for LXA4 and 
5-LO + 15-LO for LXB4). Other polyunsaturated fatty acids, e.g., 
ω-3 docosahexaenoic acid, are similarly metabolized to protec-
tins, resolvins, or maresins. It is interesting that following COX-
1 inhibition by NSAIDs, the lipoxygenase activity of this enzyme 
is retained; however, stereoselectivity of the oxidation is altered. 
A series of aspirin-triggered 15-R lipoxins or their ω-3-derived 
analogs also has a potent anti-inflammatory activity.10
5-HETE
LTA4
LTC4 synthaseLTA4-hydrolase
γ-glutamyl transpeptidase
LTD4 Dipeptidases
LTC4 
LTE4 
Fig. 3. A 5-LO product, 5-HETE, or its unstable precursor 5-HpETE is oxidized by 
the same enzyme to leukotriene A4 (LTA4). In neutrophils and monocytes, LTA4 
hydrolase reduces LTA4 to leukotriene B4 (LTB4). Cells expressing leukotriene C4 
synthase (eosinophils, mast cells, and platelets) produce leukotriene C4 (LTC4). 
This cysteinyl leukotriene is metabolized to leukotriene D4 (LTD4) and leukotri-
ene E4 (LTE4) by various petidases.
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BIOLOGICAL ACTIVITY OF EICOSANOIDS
The biological activity of eicosanoids requires expression of 
their specific receptors. There are 2 receptors for CysLTs (CysL-
TR1 and CysLTR2), and 2 receptors for LTB4 (BLTR1 and 
BLTR2). Each prostaglandin has at least 1 specific receptor; 
however, there are 4 different PGE2 receptors (EP1-4) and 2 
PGD2 receptors (DP1 and DP2).11 All these cellular proteins be-
long to a family of 7-transmembrane domain receptors, cou-
pled with G proteins (G protein- coupled receptors [GPCR], Ta-
ble). Pro-resolutionary eicosanoids also have their own recep-
tors, e.g., FPR2/ALX. This explains a variety of biological effects 
caused by eicosanoids, which may either stimulate or inhibit 
cyclic AMP production by coupling with Gαs or Gαi subunits of 
the receptor, or release intracellular calcium by Gαo also leading 
to activation of protein kinases. A complex mechanism of sig-
naling by eicosanoids, well studied on the cellular level, in-
volves not only regulated biosynthesis of these mediators but 
also changes in their receptor densities.12 This may explain their 
highly variable biological effects in the organism, not always 
predictable using in vitro experiments. 
EICOSANOIDS IN THE AIRWAYS
The lung has its own compartments for eicosanoid biosynthe-
sis. Respiratory epithelium produces and releases eicosanoids 
in a polarized pattern. Prostaglandins are transported passively 
to the luminal surface, whereas HETEs are released to the baso-
lateral one.13 Respiratory disorders are accompanied by disrup-
tion of the epithelial tight junctions and increased paracellular 
flux, or ultimately by increased shedding of epithelial cells ac-
companied by proliferation of epithelial progenitors.14 This 
might be reflected by changes in the local concentration of 
eicosanoids. During proliferation of epithelial cells, COX-2 ac-
tivity is increased; however, it becomes down-regulated in the 
fully differentiated mucociliary epithelium. Under Th2-type 
conditions mimicked by interleukin (IL)-4 and IL-13, a potent 
induction of 15-HETE activity is observed, whereas 5-LO is 
present in differentiated cells, but not induction.13 These Th2-
type cytokines also suppress PGE2 production; however, ex-
pression of COX-1 do not change and only COX-2 transcription 
decrease. Thus, respiratory epithelium has both cyclooxygen-
ases activities. However, eicosanoids are also produced by oth-
er structural cells of the respiratory tract. Bronchial fibroblasts 
have activity of COX-1 and capability to induce COX-2.15 Airway 
smooth muscle cells also express prostanoid synthases and ac-
tively contribute to epithelial regulation producing PGE2.16 In-
flammatory cells, infiltrating the lung, are an important source 
of eicosanoids, all expressing active metabolic pathways for 
eicosanoid biosynthesis. 
CLINICAL STUDIES ON EICOSANOIDS IN ASTHMA
In clinical asthma studies, the most relevant are biological 
samples collected directly from the asthmatic airways. These 
include bronchoalveolar lavage fluid (BALF), induced sputum 
(IS), and exhaled breath condensate (EBC). Each material sam-
pled has inherent advantages and drawbacks. BALF has to be 
collected during an invasive procedure of bronchofibroscopy, 
and there is no widely accepted method to compensate for a 
variable recovery of the instilled saline. This may lead to some 
dilution errors, usually not exceeding an order of magnitude in 
the measured concentration of mediators. IS collection proce-
dure is time- consuming and requires a good cooperation of 
Table. G-protein-coupled receptors for lipid mediators share homology with chemokine receptors
Receptor Ligands Function and cell distribution
CC- and CXC-type chemokines e.g. CCR5; CXCR2 MIP-1α, MIP-1β, RANTES (CCL3, CCL4, CCL5);  
IL-8, MIP-2α, MIP2β, ENA-78
Lymphocyte and dendritic cell chemotaxis; mast cell and 
neutrophil chemotaxis
Leukotriene B4 receptors, e.g., BLT1 and BLT2 LTB4; 12-hydroxy heptadeca-trienoic acid (12-HHT), 
12-HETE, 15-HETE (BLT2 only)
Neutrophil chemotaxis, maintenance of epithelial barrier 
(BLT2)
OXER1 5-oxo-ETE, 5-HpETE, 5-HETE Eosinophil chemotaxis, superoxide formation
Pro-resolving receptors, e.g., FPR2/ALXR, 
ChemR23, FPR1, FPR3, and GPR32
LXA4, LXB4; aspirin triggered 15-epi-LXA4,  
protectins, resolvins
Non-phlogistic activation of phagocytosis of macrophages, 
chemotaxis, inhibition of IL-8 production
CysLTs receptors, e.g., CysLT1 and CysLT2 LTC4, LTD4, LTE4 Bronchoconstriction (CysLT1), vascular permeability,  
mucus secretion, chemotaxis and release of mediators 
(myeloid cells)
Prostanoid receptors, e.g., EP1, EP2, EP3, EP4, TP, 
DP1, FP, and IP
PGE2, TxA2, PGD2, PGF2, PGI2 Anti-inflammatory (EP2, EP4, IP) or pro-inflammatory:  
broncho- and vasoconstriction (EP1, EP3, TP, FP), 
Dual nucleoside/cysteinyl leukotrienes receptor 
GPR17
Uridine diphosphate, LTC4, LTD4, LTE4 Ischemia-reperfusion injury, expressed on glia and  
macrophages
DP2/CRTH2 PGD2, 13,14-dihydro, 15-keto-PGD2 Eosinophil and innate lymhoid cell chemotaxis, activation 
and degranulation
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the patient, but is well tolerated. Induction of sputum is facili-
tated by inhalation of hypertonic saline solution, and is fol-
lowed by immediate laboratory preprocessing during which 
expectorated mucus plugs are manually separated from saliva. 
Next, the sputum sample is weighted and solubilized using a 
constant proportion of a reducing agent solution (dithiothreitiol 
– [DTT]). Measurements of IS lipid mediators concentrations 
are more reproducible, but may be biased if the procedure is re-
peated within a short period of time. EBC is collected in a cool-
ing trap as a condensed water vapor. It contains a small admix-
ture of aerosol from the epithelial lining fluid. This aerosol is 
produced in the smaller diffusive airways by their collapse dur-
ing inhalation and subsequent inflation causing detachment of 
the opposite airway surfaces during exhalation, following phys-
iological changes in intrabronchial pressure. We learned that 
EBC can credibly reflect a baseline production of lipid media-
tors in the airways. However, the mechanism by which EBC 
carries admixture of the epithelial lining fluid aerosol is depen-
dent on the pattern of ventilation. A decrease in the airflow dur-
ing bronchoconstriction can change concentration of media-
tors.17 For example, a rise in eicosanoids is poorly reflected dur-
ing a positive challenge procedure in aspirin-hypersensitive 
subjects. The upper respiratory tract, including nasal and para-
nasal cavities, has a histological structure of epithelium similar 
to the bronchi. Nasal lavage can be used as a source of surro-
gate material to study lipid mediators in asthmatics. It has the 
advantage that a time series of samples can be analyzed. It has 
been shown in AERD that CysLTs release reaches their maxi-
mal values in the nasal lavage 30 minutes after lysine-aspirin 
instillation, in parallel with the rise in eosinophil cationic pro-
tein (ECP). Symptoms of sneezing, nasal congestion and rhi-
norrhea appear much faster as the total nasal symptom score is 
already elevated after 10 minutes.18 In another study, increases 
in tryptase and PGD2 are also observed, whereas PGE2 decreas-
esas ECP increases.19
There are many problems in the assessment of the effect of 
eicosanoids on the systemic level. A simple venous blood sam-
pling procedure can activate platelets and bias measurements of 
lipid mediators. If done properly, it requires collection using 
tubes with internal deuterated standards and anticoagulants 
immediately cooled on ice, followed by separation of plasma. 
Thus, it is commonly preferred to quantify eicosanoid metabo-
lites in urine. However, prostaglandins, isoprostanes, and pro-
resolutionary eicosanoids all undergo extensive inactivation be-
fore excretion with urine.20 The urinary products of their break-
down are β-oxidation metabolites. The most abundant urinary 
prostanoid metabolites have the backbone shortened by 4 car-
bons and are named tetranors. The advantages of measure-
ments of these liver or kidney oxidation metabolites are their 
stability and credible estimation of the whole systemic produc-
tion of parental compounds. An exception is LTE4,  which is also 
secreted in urine and reflects the systemic production of CysLTs.
LIPID MEDIATORS IN SPECIFIC ASTHMA PHENOTYPES
Eicosanoids were studied in exercise-induced asthma be-
cause samples of EBC21 or urine showed increase in CysLTs re-
lated to the severity of symptoms following bronchoconstric-
tion.22 This reflected bronchial mast cell activation by a non-im-
munological mechanism. There is also an increase in anti-in-
flammatory PGE2 and PGD2 systemic production after eucap-
nic hyperventilation-precipitating bronchoconstriction. This 
may explain the improved symptoms of exercise repeated with-
in hours.20 It has been also shown that this phenotype depends 
on epithelial injury and increased epithelial 15-LO activity. De-
creased lipoxin biosynthesis and isoprostane overproduction 
are also implicated in exercise-induced asthma.23
Asthmatic inflammation is a multicellular process involving 
both bronchial tissue and infiltrating inflammatory cells. In al-
lergic asthma, immediate immunological reaction activates 
bronchial mast cells and results in bronchoconstriction, in-
creased mucus secretion, edema, and cough. All these symp-
toms are evoked by 2 categories of mediators: preformed medi-
tators, such as histamine, released by exocytosis and mediators 
produced by ongoing biosynthesis like eicosanoids. Contribu-
tion of each of these two mechanisms is complementary and 
variable. In clinics, neither inhibition of histamine receptors 
nor eicosanoid pathway effectively abolishes immediate reac-
tions. The limited efficacy of leukotriene-modifying drugs in-
hibiting 5-LO activity or antagonizing CysLTR1 can be attribut-
ed to individual variability of these mechanisms and a high in-
terindividual difference in leukotriene pathway activity. Urinary 
LTE4 can vary from less than hundred picograms per milligram 
creatinine in healthy subjects to several thousands in some 
asthmatic patients.24 There is also a debate whether CysLTs are 
produced by mast cells in the lung or by eosinophils. Recent 
studies on the eicosanoid handprint in different phenotypes of 
asthma showed that IS eicosanoid levels correlate well with pe-
ripheral blood eosinophilia and sputum eosinophil count.25 
However, mast cells are also the abundant source of CysLTs. On 
the systemic level, excretion of urinary LTE4, an ultimate me-
tabolite of LTC4 and LTD4, is elevated in mast cell disorders.26 
Thus, both cells contribute to the production of these potent 
bronchoconstrictors in asthma. Mast cells also produce PGD2. 
This prostaglandin does not directly constrict bronchi through 
the DP1 receptor but stimulates sensory C-fibres to induce 
cough reflex.27 However, PGD2 can also activate the thrombox-
ane receptor TP which is the least specific prostanoid receptor 
capable of contracting airway smooth muscle cells. Another bi-
ological effect of PGD2 is chemoattraction of eosinophils and 
innate lymphoid cells (ILC), a recently defined subset of innate 
immune cells. In particular, type-2 ILC (ILC-2) have the DP2 re-
ceptor (also named chemoattractant receptor expressed on 
Th2 cells, such as CRTH2 or GPR44).28 These cells are sources 
of IL-13 and IL-5 responsible for the persistence of allergic in-
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flammation in the airways. Powell and Rokach29 discovered a 
novel eicosanoid which is another chemoattractant of eosino-
phils and more potent than PGD2. A product of 5-LO, 5-HETE, 
can be oxidized by a specific 5-HETE dehydrogenase to form 
5-oxo-ETE. It was experimentally shown that 5-oxo-ETE acti-
vates and attracts eosinophils by a specific receptor named 
OXER1, previously cloned as an orphan receptor, GPCR48. 
Studies on 5-oxo-ETE and its receptor suggest that this eico-
sanoid can be responsible for eosinophilic inflammation of the 
airways. However, lack of the receptor homolog in mice is a ma-
jor obstacle to investigate a conventional murine model of asth-
ma. Using a feline model of allergic asthma in which cats were 
sensitized to Bermuda grass allergen, cells from BALF can pro-
duce 5-oxo-ETE.30 This lipid mediator induce chemotaxis of eo-
sinophils at much lower concentrations than LTB4.
It remains unexplained why asthmatics are oversensitive to 
LTE4. Studies on the existence of a distinct LTE4 receptor over-
expressed in asthma revealed some candidates. Nonspecific 
stimulation of adenosine receptors by LTE4 was proposed as the 
mechanism for a receptor cross-talk between CysLT1 and puri-
nergic receptor P2Y12.31 However, subsequent studies did not 
support the explanation for enhanced asthmatic bronchial 
constriction in response to LTE4.32 Di Capite et al.33 proposed a 
mechanism in which CysLTs activation of mast cells mediated 
by the CysLTR1 receptor facilitate opening of calcium-release 
to activate calcium channels responsible for high sensitivity to 
this class of eicosanoid mediators in asthma.
It is frequently difficult to identify a single factor for chronic 
course of asthma in adults. Despite elevated total serum IgE, el-
evated Th2-type cytokines in the airways and allergic sensitiza-
tion, asthma symptoms persist even after allergen avoidance. A 
protracted allergic inflammation is accompanied by induction 
of eicosanoid biosynthesis; however, no uniform pattern of 
these mediators can be identified. 
Inflammatory phenotypes of asthma were proposed based on 
IS cellular content. However, prospective observational studies 
showed that around 40% patients changed their cellular phe-
notype of asthma during the observation period.34 This presen-
tation of cellular inflammatory phenotypes can correlate with 
IS eicosanoid profiles only to some extent. However, if data on 
IS differential cell count were combined with the lipid mediator 
profile some interesting conclusions emerged.35 First, mild to 
moderate asthma can be distinguished from severe disease. 
The most distinct is the phenotype of severe eosinophilic asth-
ma accompanied by chronic rhinosinusitis (CRS) in subjects 
with a low prevalence of atopy (26%). Most of them (86%) also 
manifest hypersensitivity to NSAIDs, and their asthma remains 
poorly controlled. These patients require high doses of inhaled 
corticosteroids, and 14% asthmatics need systemic corticoste-
roids. In this phenotype, eosinophilia is elevated both in pe-
ripheral blood and in IS. The profile of lipid mediators is domi-
nated by high levels of LTD4, LTE4, and PGD2. This form of asth-
ma represents classical AERD. However, there is another phe-
notype of severe asthma, without elevated eosinophil count in 
IS. The sputum is either neutrophilic or paucicellular, and two-
thirds of asthmatics also have CRS and atopy is a common fea-
ture (65%). Asthmatics are mostly women, frequently over-
weight. More than one- third of these asthmatics have a history 
of asthma starting in childhood. Despite treatment with oral 
corticosteroids, these asthmatics have the worst control of the 
disease. In this specific phenotype, CysLTs or PGD2 is not ele-
vated in IS, and the eicosanoid profile is marked only by a high-
er PGE2 concentration. It is noticeable that some of these pa-
tients also show hypersensitivity to NSAIDs. These 2 severe 
asthma phenotypes contrast with a mild to moderate asthma 
which is predominantly atopic and well controlled using low 
doses of ICS. None of these asthmatics have CRS, and IS shows 
no elevated eosinophil count or paucigranulocytic or neutro-
philic one. None of these asthmatics have hypersensitivity to 
NSAIDs. In this form of asthma, no alterations in lipid media-
tors levels could be detected during a stable period of the dis-
ease. Among cellular and eicosanoid phenotypes of asthma, 
another mild to moderate form exists with a frequent CRS co-
morbidity, but without any other characteristic features of IS 
differential cell count or eicosanoid profile. These asthmatics 
rarely have atopy and their disease course is intermittent or 
moderate at most. It is surprising to observe sometimes NSAIDs 
hypersensitivity also within this group of asthmatics. Thus, spu-
tum inflammatory cells match only partially with the profile of 
eicosanoids in the same samples. It seems, however, that both 
classifications correctly distinguish eosinophilic phenotypes. 
The major problem of phenotyping in asthma is classification 
of asthmatics with mixed or paucicellular sputum. It can be 
concluded, that a low content of eicosanoid lipid mediators, 
namely LTD4, LTE4, PGD2, and PGE2, predicts a favorable course 
of the disease, with good control of symptoms. This is not relat-
ed to NSAIDs intolerance, atopy, or accompanying CRS. Using 
only urinary LTE4 excretion as a variable complementary to 
clinical characteristics of patients, similar subtypes of AERD 
can be distinguished.36
Hypersensitivity to NSAIDs like AERD has heterogenous pre-
sentations in asthmatics. Some important observations were 
recently published on the pathomechanism of this specific type 
of asthma. Liu et al.37 managed to test a murine model of the 
disease. It required to sensitize mice with a common house 
dust mite allergen and to ablate PGE2 production by microsom-
al PGE2 synthase knockout. A challenge with aspirin causes, in 
these animals, degranulation of mast cell and bronchoconstric-
tion. There are post-challenge elevations in histamine and 
CysLTs. The same research group suggested that the major 
source of CysLTs in AERD patients could be transcellular bio-
synthesis by platelets adhering to peripheral blood granulo-
cytes.38 Peripheral blood granulocytes of AERD asthmatics are 
also refractory to inhibition by PGE2.39 However, studies on na-
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sal mucosa from AERD patients demonstrated another intrigu-
ing feature of the disease. Eosinophils infiltrating the upper re-
spiratory tract not only produced CysLTs but also secreted 
interferon-γ.40 These mediators were absent in cells isolated 
from healthy controls or patients with chronic hyperplastic eo-
sinophilic sinusitis as a disease control. Interferon-γ prestimu-
lation of eosinophils was also necessary to activate CysLTs bio-
synthesis in eosinophils experimentally matured from the 
blood progenitors, and these cells also responded to ketorolac, 
another NSAID tested.41
Changes in the eicosanoid profile of IS immediately after pos-
itive bronchial provocation with lysine-aspirin are very interest-
ing. These may help understand the initial reaction responsible 
for asthmatic attack in AERD patients. Biosynthesis of PGE2 in 
bronchi seems to be extremely sensitive to inhibition by acetyl-
salicylic acid.25 An inhaled lysine-aspirin dose of as low as 17 
mg on average causes bronchoconstriction with an FEV1% de-
crease exceeding 20%. Interestingly, according to individual hy-
persensitivity to NSAIDs, smaller doses of the drug frequently 
elicit more severe contraction of bronchi. Despite a small total 
dose of the drug inhaled, a significant decrease in PGE2 sputum 
concentration is observed only in AERD. A much higher dose 
of acetylsalicylic acid inhaled by aspirin-tolerant asthmatics 
causes a decrease in the metabolite 13, 14-dihydro, 15-keto-
PGE2,without PGE2 change. This 13, 14-dihydro, 15-keto-PGE2 
is an intermediate metabolite of PGE2 inactivation pathway. It is 
surprising that in AERD patients, PGD2 is not rising after the 
drug provocation, although the prostaglandin remains elevat-
ed. Similarly, no changes in PGD2 metabolites are observed fol-
lowing inhalation of lysyl-aspirin. Thromboxane production is 
suppressed in aspirin-tolerant asthmatics receiving a full dose 
of lysine-aspirin, whereas no differences in the sputum levels of 
11-dehydro-TXB2 are observed in AERD patients. Before the 
challenge, overproduction of CysLTs is manifested in AERD by 
higher LTE4, but concentrations of LTC4 and LTD4 in IS are com-
parable to those of aspirin-tolerant asthmatics. However, fol-
lowing a positive challenge in AERD group, a significant in-
crease is noted for all CysLTs. The bronchial provocation does 
not affect the level of 5-HETE or 15-HETE in IS and only 12-
HETE is decreased after provocation with acetylsalicylic acid, 
but this appears in both groups of asthmatics. An unexpected 
finding of the study is that overproduction of CysLTs does not 
correlate with the level of 5-HETE, a 5-LO pathway substrate. 
Following provocation with acetylsalicylic acid, LTB4 is the only 
eicosanoid mediator of 5-LO pathway which is decreased in 
AERD patients. Collectively, CysLTs overproduction occurs at 
the expense of LTB4 biosynthesis. The total 5-LO pathway eico-
sanoids show no changes after the provocation. It is highly 
plausible that following NSAIDs exposure, there is a dramatic 
shift in the profile of eicosanoids from LTB4 to CysLTs in the 
bronchi of AERD asthmatics due to enhanced transcellular bio-
synthesis. This might be explained by activation of platelets and 
their adherence to granulocytes. In fact, such an observation on 
elevated fraction of neutrophil-platelet aggregates in peripheral 
blood was described previously by Laidlaw et al.,38 demonstrat-
ing activated platelets in the granulocyte-infiltrated nasal mu-
cosa. There remains, however, a pivotal question regarding the 
specificity of this finding and the reason for the enhanced ag-
gregation between platelets and granulocytes in AERD. Results 
from allergen challenge (birch pollen) show no decrease in 
BALF LTB4 concentration. On the contrary, a trend toward in-
creased LTB4 was accompanied by a robust response in 15-LO 
metabolites.42 Biosynthesis of CysLTs by the neutrophil-platelet 
aggregates seems a distinct feature of AERD. However, aspirin 
remains the most common antiplatelet cardioprotective drug 
administered. It irreversibly inhibits platelet COX-1 and de-
creases production of prothrombotic TXA2. Ex vivo experi-
ments demonstrated the resistance of peripheral blood granu-
locytes from AERD subjects to PGE2 inhibition of transcellular 
CysLTs production and increased granulocyte-platelet aggre-
gates.39 It is speculated that this resistance to anti-inflammatory 
activity of PGE2 might be related to altered EP receptor signal 
transduction and defects in 5-LO regulation by protein kinase 
A. However, we recently observed an inexplicable alteration in 
PGE2 biosynthesis during provocation of AERD patients with 
aspirin. This discovery may offer another explanation for the 
mechanism underlying the activation of platelets or even a di-
rect constriction of bronchi in AERD.43 In EBC collected before 
and after inhalation challenge with lysine-aspirin, we identified 
an isomer of PGE2. While 8-iso-PGE2 is characterized by cis-
conformation of the 2 aliphatic chains at the cyclopentane ring, 
the regular PGE2 produced by a concerted action of cyclooxy-
genases and PGE synthases has trans-conformation. Thus, 
8-iso-PGE2 is similar in its stereochemistry to 8-iso-PGF2α, the 
most commonly measured isoprostane product of arachidonic 
acid by non-enzymatic oxidation (Fig. 4). Also, 8-iso-PGE2 is a 
pro-inflammatory prostanoid, with broncho- and vasoconstric-
tory properties and has a similar activity as 8-iso-PGF2α.44 Fol-
lowing bronchoconstriction induced by the challenge test, we 
noticed a specific increase the EBC concentration of 8-iso-PGE2 
only in AERD patients, whereas no changes in 8-iso-PGF2α were 
observed. This isoprostane production might be an initial event 
triggered by aspirin, activating platelet-neutrophil interaction 
and resulting in the release of CysLTs. Moreover, 8-iso-PGE2 can 
directly stimulate smooth muscle contraction. It would be nec-
essary to investigate why this isoprostane is overproduced fol-
lowing exposure to NSAIDs in hypersensitive subjects. In vitro 
studies on macrophages stimulated with COX-2-inducing com-
pounds, such as bacterial lipopolysaccharides (LPS), docu-
mented production of 8-iso-PGE2 within the first hours of the 
stimulation. We had similar observations on respiratory epithe-
lial cells stimulated with LPS. During the induction of pros-
tanoid biosynthesis, PGE2 accumulation was accompanied by a 
parallel increase in 8-iso-PGE2. Thus, 8-iso-PGE2 production 
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occurs during induction of COX-2 enzyme, probably because 
the intracellular supply of arachidonic acid exceeds catalytic 
activity of cyclooxygenases. This is also due to inhibition of co-
expressed COX-1 by NSAIDs. It requires a low basal level of 
COX-2, whose induction defect was recently described in fibro-
blasts of nasal polyps from AERD patients.45 This defect is at-
tributed to a lowered density of the interleukin-1 receptor I and 
a failure to induce COX-2 and membrane-associated PGE syn-
thase (mPGES). All these abnormalities can be corrected in vi-
tro by artificial expression of EP2, the PGE2 receptor type-2, 
which has been shown to be associated with AERD in genetic 
studies. The appropriate cellular model of these eicosanoid 
anomalies may help prove the mechanism of NSAIDs-triggered 
bronchoconstriction in AERD. Respiratory epithelial cells col-
lected from asthmatic patients tend to maintain their epigene-
tic marks for several passages. Recently, these primary cell cul-
tures have been obtained by nasal brushing instead of bron-
chofiberoscopy.47 However, the fundamental question regard-
ing the mechanism of dysregulation of COX-2, mPGES, and 
EP2 as a plausible cause for AERD will require more studies.
FUTURE DIRECTIONS IS THE RESEARCH ON EICOSANOID 
MEDIATORS IN ASTHMA
The last decade progress in our understanding of the role of 
eicosanoids in asthma have stimulated development of meth-
ods for screening and measurements of these lipid mediators 
in complex biological matrices. It is rather improbable that any 
single eicosanoid or even a complex profile of eicosanoids 
could provide explanation for the mechanism of asthmatic in-
flammation. It remains rather a practical question whether pro-
filing of eicosanoids in clinical samples will offer any advantag-
es over other diagnostic methods. One of the currently tested 
biomarkers is urinary LTE4 that promises a diagnostic validity 
in distinguishing AERD patients from aspirin-tolerant asthmat-
ics. The sensitivity and specificity of this biomarker seem to be 
limited. From the clinical and practical points of view, a limited 
positive predictive value of urinary LTE4 precludes any safe rec-
ommendation for the tolerance of NSAIDs to a patient at risk 
for the disease. Another promising prediction based on urinary 
metabolites of eicosanoids is that systemic production of pros-
taglandins measured as a tetranor-PGE2 metabolite in urine, in 
children with wheezing, correlates with their risk for asthma. 
Systemic overproduction of PGE2 is associated with a sup-
pressed ability of airway macrophages to phagocyte particulate 
matter carbon.46 A decreased number of the airway macro-
phage carbon particles was found in IS cytospin differential 
counts of asthmatic children. The impaired phagocytosis nega-
tively correlates with disease severity as well as urinary excre-
tion of 13, 14-dihydro-15-keto-tetranor-PGE2. Inhibition of 
macrophage phagocytosis by a micromolar concentration of 
PGE2, but not PGD2, was confirmed by in vivo experiments and 
is consistent with its anti-phlogistic activity. Ultimately, it might 
be expected that some rapid methods for assessment of eico-
Fig. 4. During induction of cyclooxygenase-2 expression, a cis-isomer of prostaglandin E2 (PGE2) is produced. A. The chemical structure of PGE2 having trans confor-
mation of aliphatic chains at the cyclopentane ring. B. 8-iso-PGE2 with cis-conformation. C. Human bronchial epithelial cells were cultured at the presence of 
interleukin-1β (recombinant IL-1β 3ng/mL) or bacterial lipopolysaccharide (Pseudomonas aeruginosa LPS, 1β g/mL), and 8-iso-PGE2 accumulated in the culture medi-
um with a peak concentration between 3 and 18 hours, depending on the stimulus.
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sanoid mediators in EBC or IS will enable screening of asthmat-
ics to better characterize their inflammatory phenotypes or 
even to monitor the course of the disease.25,48 A recent meta-
analysis on a diagnostic value of volatile organic compounds in 
the exhaled breath showed some encouraging results, although 
methods for eicosanoid detection and quantification in the ex-
haled breath still require collection of EBC, IS, or urine and la-
borious measurement techniques.49
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